Viking Therapeutics, Inc. Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX

Kedudukan dalam Saham #4557
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Harga Saham
$26.38
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$3.35B
Perubahan (1 hari)
-1.23%
Perubahan (1 tahun)
-16.04%
Negara
US
Perdagangan Viking Therapeutics, Inc. (VKTX)

Kategori

Healthcare
Sejarah harga saham bagi Viking Therapeutics, Inc. (VKTX)
Harga penutupan tertinggi: $27.60 pada 2026-10-01

Harga penutupan terendah: $8.59 pada 2015-04-01
Sejarah harga saham Viking Therapeutics, Inc. dari 2015 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) -7.84%
2025 -20.83%
2024 152.59%
2023 215.71%
2022 16.84%
2021 -21.08%
2020 -20.48%
2019 -10.51%
2018 130.53%
2017 246.93%
2016 -60.36%
2015 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
$527.18 23.62%
US
$251.29 835.90%
US
$137.04 -4.33%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH